ClinicalTrials.gg
Not yet recruitingNCT07748364Updated Aug 5, 2026

Glofitamab in B-NHL Using Mid-Therapy Intratumoral Transcriptomics

A Phase 2 interventional study of Glofitamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma and Relapsed/Refractory Mantle Cell Lymphoma, sponsored by Joshua Brody. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-05.

Sponsored by Joshua Brody · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies testing glofitamab in Lymphoma, Large B-Cell, Diffuse — 14 open to participants now, 19 under way, 1 of them phase 3. glofitamab · Lymphoma, Large B-Cell, Diffuse.

Planned enrollment
18th of 20
16 · median 40
Started
2026
with 7 others
Phase 2
16 of 20
12 open now
Primary completion
2027-07
later than 6 of 18 live
Registered
19th of 20
by date
Lead sponsor
1 of 20
Joshua Brody

Among the 20 studies testing glofitamab in Lymphoma, Large B-Cell, Diffuse, this one is the 18th largest by planned enrollment, is one of 8 that started in 2026, is one of 16 in phase 2, reaches primary completion later than 6 of the 18 other live ones, and was the 19th registered.

Lymphoma, Large B-Cell, Diffuse

1,873 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

14 of the 20 studies testing glofitamab in Lymphoma, Large B-Cell, Diffuse are open now, in 8 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About glofitamab

glofitamab: first FDA approval 2023 (COLUMVI), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 265 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 176 (66%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing glofitamab in Lymphoma, Large B-Cell, Diffuse, or all of them as a file.
02

Study summary

This trial will enroll patients with relapsed/refractory DLBCL and MCL, with the opportunity to receive single-agent glofitamab as early as the second-line. Patients will have superficially accessible disease to enable core-needle biopsy prior to therapy initiation, and on cycle 1 day 15 and cycle 2 day 1 of therapy administration to enable high throughput molecular profiling of disease and immune dynamics while on treatment.

Read the detailed description

This trial will enable patients with relapsed/refractory disease to receive glofitamab at an earlier line than is currently approved in the United States. Overall, it is anticipated that the benefits of glofitamab as a single agent will outweigh its potential risks, particularly given the poor prognosis of patients with relapsed/refractory DLBCL or MCL who have failed SoC regimens. Glofitamab offers high rates of complete response with durable disease control and favorable toxicity profile relative to current SoC regimens, such as chemotherapy or autologous stem cell transplantation.

03

Conditions studied

  • Relapsed/Refractory Diffuse Large B-cell Lymphoma
  • Relapsed/Refractory Mantle Cell Lymphoma

Keywords

  • DLBCL (diffuse large B-cell lymphoma)
  • MCL (mantle cell lymphoma)
  • relapsed
  • refractory
  • GLOFITAMAB
  • TRANSCRIPTOMICS
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with confirmed diagnosis of aggressive CD20(+) B-NHL,
  • including DLBCL and MCL.
  • Stage II, III or IV by Ann Arbor Classification.
  • Superficially accessible lesion for core-needle , e.g. cervical, axillary,
  • inguinal, subcutaneous.
  • Disease that has progressed (clinically or radiographically) after standard-of-care
  • prior therapy, including anthracycline-based therapy for DLBCL and anti-CD20
  • mAb-based therapy for all histologies.

Exclusion criteria

Exclusion Criteria:

Patients who meet any of the following criteria will be excluded from study entry:

  • to any of the individual components of glofitamab or history of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products
  • Any prior treatment with a BsAb targeting CD3 and CD20
  • Prior hematopoietic stem cell transplantation or solid organ transplantation
  • Prior treatment with systemic immunotherapeutic agents, including but not limited to, radio-immuno-conjugates, antibody-drug conjugates, immune/cytokines and monoclonal antibodies (mAbs) (e.g., anti-cytotoxic T lymphocyte associated protein 4, , and anti-PD-L1) within 4 weeks or five half-lives of the drug, whichever is shorter
  • Treatment with CAR-T therapy within 30 days prior to first dose of glofitamab
  • Any therapy for the purposes of treating cancer within 28 days prior to the start of Cycle 1
  • Prior radiotherapy to the mediastinal/pericardial region Radiotherapy to non-target lesion sites will be permitted.
  • use >50 mg/day of prednisone or equivalent, for purposes other than lymphoma symptom control

    • Participants receiving corticosteroid treatment with >50 mg/day of prednisone or equivalent for reasons other than lymphoma symptom control (e.g., rheumatoid arthritis) must be documented to be on a stable dose of at least 4 weeks duration prior to the start of Cycle 1.

      • Corticosteroid therapy for control of cancer symptoms or side effects of prior treatment (e.g., nausea or B-symptoms) is permitted.
      • The use of inhaled corticosteroids is permitted.
      • The use of mineralocorticoids for management of orthostatic hypotension is permitted.
      • The use of physiologic doses of corticosteroids for management of adrenal insufficiency is permitted.
    • Participants who require lymphoma symptom control during screening may receive steroids in the following manner:

      • Up to 50 mg/day of prednisone or equivalent may be used for lymphoma symptom control during screening, including prior to finalization of staging (not included as part of pre-phase treatment).
      • If glucocorticoid treatment is urgently required at higher doses for lymphoma symptom control prior to the start of study treatment, tumor assessments must be completed prior to initiation of 50-100 mg/day of prednisone or equivalent. Prednisone 50-100 mg/day or equivalent may be given for a maximum of 10-14 days as a pre-phase treatment. As part of the pre-phase treatment, vincristine may not be administered.
  • History of other that could affect compliance with the protocol or interpretation of results:

    • Participants with a history of curatively treated basal or squamous cell carcinoma or melanoma of the skin or in situ carcinoma of the cervix at any time prior to the study are eligible.
    • Participants with any malignancy appropriately treated with curative intent and the malignancy has been in remission without treatment for > 2 years prior to enrollment are eligible.
    • Participants with low-grade, early-stage prostate cancer (Gleason score 6 or below, Stage 1 or 2) with no requirement for therapy at any time prior to study are eligible.
  • Significant or extensive history of cardiovascular disease such as Class III or IV cardiac disease or Objective Assessment Class C or D, myocardial infarction within the last 3 months prior to the start of Cycle 1, unstable arrhythmias, or unstable angina
  • Recent major surgery (within 4 weeks prior to the start of Cycle 1), other than for diagnosis
  • Current or past history of CNS disease, such as stroke, epilepsy, CNS vasculitis or neurodegenerative disease Participants with a history of stroke who have not experienced a stroke or in the past 2 years and have no residual neurological deficits, as judged by the investigator, are allowed.
  • Current or past history of CNS lymphoma
  • Known or suspected history of hemophagocytic lymphohistiocytosis (HLH)
  • Current or past history of Waldenström macroglobulinemia
  • History or presence of an abnormal that is in the investigator's opinion
  • Patients with known or suspected active infection, or reactivation of a latent infection, whether bacterial, viral (including, but not limited to, SARS-Cov-2, Epstein-Barr virus (EBV), cytomegalovirus (CMV), , and ), fungal, mycobacterial, or other pathogens (excluding fungal infections of nail beds) or any major episode of infection requiring hospitalization or treatment with IV antibiotics (for IV antibiotics this pertains to completion of last course of antibiotic treatment) within 4 weeks of dosing
  • History of treatment-emergent immune-related adverse events associated with prior immunotherapeutic agents, as follows:

    • Grade 3 or higher adverse events with the exception of Grade 3 endocrinopathy managed with replacement therapy.
    • Grade 1-2 adverse events that did not resolve to baseline after treatment discontinuation.
  • Clinically significant liver disease, including active viral or other hepatitis or cirrhosis
  • Illicit drug or alcohol abuse within 12 months prior to screening, in the investigator's judgment
  • Any of the following abnormal laboratory values (unless any of these abnormalities are due to underlying lymphoma):

    • or PT > 1.5 x (ULN) in the absence of therapeutic anticoagulation.
    • PTT or aPTT >1.5 x ULN in the absence of a lupus anticoagulant.
    • Serum and ALT >2.5 x ULN.
    • Total >1.5 x ULN. Participants with documented Gilbert disease may be enrolled if total bilirubin is > 3.0 x ULN.
  • Live, attenuated vaccine within 4 weeks before study treatment infusion on Day 1 of Cycle 1 or anticipation that such a live, attenuated vaccine will be required during the study. during the study and until participants B cells recover, are prohibited Influenza vaccination should be given during influenza season only. Participants must not receive live, attenuated influenza vaccine at any time during the study treatment period.
  • Suspected active or latent tuberculosis (as confirmed by a positive interferon-gamma release assay)
  • Positive test results for chronic hepatitis B infection (defined as positive hepatitis B surface antigen [HBsAg] serology) Participants with occult or prior hepatitis B infection (defined as positive total hepatitis B core antibody and negative HBsAg) may be included if hepatitis B virus (HBV) DNA is undetectable at the time of screening. Such participants must be willing to undergo HBV DNA testing on Day 1 of every cycle and every 3 months for at least 12 months after the final cycle of study treatment and appropriate antiviral therapy as indicated.
  • Positive test results for hepatitis C (hepatitis C virus [HCV] antibody serology testing) Participants positive for HCV antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.
  • Positive test results for HTLV-1
  • Participants with a history of progressive multifocal leukoencephalopathy
  • Pregnancy or breastfeeding, or intention of becoming pregnant during the study or within 18 months after pretreatment with obinutuzumab or 2 months after the final dose of glofitamab, whichever is longer
  • Positive SARS-CoV-2 test within 7 days prior to enrollment. Rapid antigen test result is also acceptable.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (estimated)

Study arms

  • Experimental
    Participants with relapsed/refractory DLBCL or MCL

    Participants will receive step-up dosing of IV infusion of glofitamab on cycle 1 day 8 (2.5 mg) and cycle 1 day 15 (10 mg), followed by full dose (30 mg) starting on cycle 2 (C2) day 1 (day 22 overall) and then days 1±3 of all subsequent 21 day cycles.

    Biological: Glofitamab

Interventions

  • BiologicalGlofitamab

    Glofitamab is a bispecific T-cell-engaging antibody, designed to bind CD20 on B-cells, and CD3 on T-cells, bringing T-cells into close contact with malignant B-cells to trigger immune-mediated killing.

    Also known as: Columvi®

06

What researchers measure

Primary outcomes

  1. Proportion of patients with an increase of CD20(-) tumor cells >= 10 fold

    Proportion of patients with an increase of CD20(-) tumor cells \>= 10-fold increase in proportion of CD20(-) lymphoma cells within 3 weeks of initiation of glofitamab therapy.

    Time frame: within 3 weeks of glofitamab therapy initiation

Secondary outcomes

  1. Transcriptional changes in tumor cells

    Transcriptional changes in tumor cells within 3 weeks of initiation of glofitamab therapy, defined as the fold-change of individual gene RNA transcript counts between timepoints.

    Time frame: within 3 weeks of glofitamab therapy initiation

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Given the complexity and exploratory nature of exploratory biomarker analyses, data derived from these analyses will generally not be provided to study investigators or patients unless required by law. The aggregate results of any conducted research will be available in accordance with the effective Investigator policy on study data publication.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Jul 2027, 10 months later.

Of 211 non-industry phase 2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 96. This study's planned 10 months is below that.

Counting every sponsor, half of 264 studies reached it within 52 months; a quarter within 35 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2026
First posted
Aug 5, 2026
StartEst.
Sep 2026
Primary completionEst.
Jul 2027
CompletionEst.
Jul 2027
Last update
Aug 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07748364
Lead sponsor
Joshua Brody
Collaborators
Genentech, Inc.
Responsible party
Joshua Brody (Professor- Hematology & Medical Oncology - ISM, Icahn School of Medicine at Mount Sinai) — Sponsor-investigator
First posted
Aug 5, 2026
Start date
Sep 2026 (estimated)
Primary completion
Jul 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Aug 5, 2026

Study contacts

Martine Van Voorthuysen
Contact
Martine.VanVoorthuysen@mssm.edu
(646) 745-6092
Joshua Brody
principal investigator · Icahn School of Medicine at Mount Sinai

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glofitamab

Start the discussion